Literature DB >> 3015015

Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts.

P Hussy, G Maass, B Tümmler, F Grosse, U Schomburg.   

Abstract

The influence of ciprofloxacin, nalidixic acid, norfloxacin, novobiocin, and ofloxacin on elements of eucaryotic DNA replication was investigated in vitro. Each of the 4-quinolones, when present in amounts of more than 100 micrograms/ml, reversibly inhibited the DNA synthesis performed by the 95 DNA polymerase alpha primase complex from calf thymus. Novobiocin at 500 micrograms/ml or at higher concentrations irreversibly inactivated DNA polymerase alpha primase complex. The accuracy of in vitro DNA synthesis in the absence of repair mechanisms was determined from amber-revertant assays with phi X174am16(+) DNA as template. The antimicrobial agents did not significantly increase the frequencies of base pairing mismatches during the course of replication, indicating that the basal mutation rate is not affected by novobiocin and the 4-quinolones. The Ki values of 50% inhibition of DNA topoisomerases from calf thymus by ciprofloxacin, norfloxacin, novobiocin, nalidixic acid, and ofloxacin were 300, 400, 1,000 or more, 1,000 or more, and 1,500 or more micrograms/ml, respectively, in the case of topoisomerase I, and the Ki values were 150, 300, 500, 1,000, and 1,300 micrograms/ml, respectively, in the case of topoisomerase II. The procaryotic topoisomerase II is approximately 100-fold more sensitive to inhibition by ciprofloxacin, norfloxacin, and ofloxacin than is its eucaryotic counterpart. Growth curves of lymphoblasts were recorded in the presence of ofloxacin and ciprofloxacin. Neither 1 nor 10 micrograms of ciprofloxacin or of ofloxacin per ml affected cell proliferation. Ofloxacin and ciprofloxacin at 100 micrograms/ml inhibited cell growth; 1,000 micrograms/ml led to cell death. No correlation exists between the antimicrobial and cytotoxic activities of the 4-quinolones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015015      PMCID: PMC180502          DOI: 10.1128/AAC.29.6.1073

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  Segregation of Lambda Lysogenicity during Bacterial Recombination in Escherichia Coli K12.

Authors:  R K Appleyard
Journal:  Genetics       Date:  1954-07       Impact factor: 4.562

2.  In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin.

Authors:  L Yang; T C Rowe; E M Nelson; L F Liu
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

3.  Two types of ribosome in mouse-hamster hybrid cells.

Authors:  C P Stanners; G L Eliceiri; H Green
Journal:  Nat New Biol       Date:  1971-03-10

4.  The induction of protein X in DNA repair and cell division mutants of Escherichia coli.

Authors:  L J Gudas
Journal:  J Mol Biol       Date:  1976-07-05       Impact factor: 5.469

5.  Escherichia coli DNA gyrase.

Authors:  R Otter; N R Cozzarelli
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Effects of novobiocin on adenovirus DNA synthesis and encapsidation.

Authors:  J C D'Halluin; M Milleville; P Boulanger
Journal:  Nucleic Acids Res       Date:  1980-04-11       Impact factor: 16.971

7.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  Nalidixic acid, oxolinic acid, and novobiocin inhibit yeast glycyl- and leucyl-transfer RNA synthetases.

Authors:  H T Wright; K C Nurse; D J Goldstein
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

9.  DNA gyrase (Topoisomerase II) from Pseudomonas aeruginosa.

Authors:  R V Miller; T R Scurlock
Journal:  Biochem Biophys Res Commun       Date:  1983-01-27       Impact factor: 3.575

10.  Dependence of mammalian DNA synthesis on DNA supercoiling. III. Characterization of the inhibition of replicative and repair-type DNA synthesis by novobiocin and nalidixic acid.

Authors:  M R Mattern; D A Scudiero
Journal:  Biochim Biophys Acta       Date:  1981-04-27
View more
  53 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.

Authors:  J F Barrett; T D Gootz; P R McGuirk; C A Farrell; S A Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

3.  Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.

Authors:  A Bredberg; M Brant; M Jaszyk
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

4.  Significance of the methyl group on the oxazine ring of ofloxacin derivatives in the inhibition of bacterial and mammalian type II topoisomerases.

Authors:  K Hoshino; K Sato; K Akahane; A Yoshida; I Hayakawa; M Sato; T Une; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

5.  Avian myeloblastosis virus reverse transcriptase inhibition by nalidixic acid.

Authors:  H Aoyama
Journal:  Mol Cell Biochem       Date:  1991-12-11       Impact factor: 3.396

6.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Limited effects of temafloxacin compared with ciprofloxacin on T-lymphocyte function.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

9.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 10.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.